Achilles Transfers Technology Assets From TRACERx NSCLC Study To AstraZeneca For $12 Mln, Stock Up

(RTTNews) - Achilles Therapeutics Plc. (ACHL), Tuesday announced that the company has transferred the commercial license of data and samples from the TRACERx Non-Small Cell Lung Cancer study to AstraZeneca Plc. (AZN) for $12 million.

Additionally, AstraZeneca will also sponsor Achilles Material Acquisition Platform, a proprietary network donor that has collected tumor tissue and blood from nearly 300 cancer patients.

Moreover, the clinical-stage biopharmaceutical company is planning to reduce the workforce and cut the size of its board as part of its strategic review.

Currently, Achilles's stock is trading at $1.08, up 10.20 percent on the Nasdaq.